GUGGENHIME ANDREW — SEC Form 4 filings
SEC reporting owner CIK 1230724. 33 Form 4 filings on record with FilingPulse; latest filed 2026-09-09.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2024-01-19 to 2026-09-09. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 43 legs across 17 filings — 176,000 shares, $14,753,177 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 71.
- Largest priced transaction: sale of 36,114 shares @ $115.26 ($4,162,608) in Vaxcyte, Inc., filed 2024-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | PRESIDENT AND CFO | 30 | — | 43 legs · 176,000 sh · $14,753,177 | 68 |
| Caribou Biosciences, Inc. (CRBU) | Director | 3 | — | — | 3 |
Form 4 filings — GUGGENHIME ANDREW
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-09 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 7,155 @ $60.36 | EDGAR |
| 2026-09-02 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,273 @ $60.74 · Tax withholding (F): 1,432 @ $61.58 | EDGAR |
| 2026-08-05 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 10,000 @ $5.35 · Sale (S): 6,956 @ $53.76 · Sale (S): 3,044 @ $54.18 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-06 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 10,000 @ $5.35 · Sale (S): 7,913 @ $57.16 · Sale (S): 2,087 @ $57.76 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 10,000 @ $5.35 · Sale (S): 10,000 @ $53 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,021 @ $59.32 | EDGAR |
| 2026-03-02 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 44,864 @ $0 · Tax withholding (F): 898 @ $61.98 · Tax withholding (F): 1,009 @ $61.98 · Grant/award (A): 74,993 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Caribou Biosciences, Inc. (CRBU) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Vaxcyte, Inc. (PCVX) | Gift (G): 61,850 @ $0 · Gift (G): 61,850 @ $0 | EDGAR |
| 2025-09-10 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 2,890 @ $32.41 | EDGAR |
| 2025-09-04 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 1,270 @ $31.56 · Tax withholding (F): 2,381 @ $31.56 · Tax withholding (F): 1,429 @ $31.56 | EDGAR |
| 2025-04-09 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 4,777 @ $20.93 · Option exercise (M): 4,777 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 22,761 @ $0 · Tax withholding (F): 1,270 @ $73.02 · Tax withholding (F): 3,809 @ $72.10 · Grant/award (A): 75,991 (derivative) @ $0 | EDGAR |
| 2025-02-21 | 4 | Caribou Biosciences, Inc. (CRBU) | Grant/award (A): 40,500 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 6,182 @ $83.64 · Sale (S): 1,818 @ $84.58 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 5,318 @ $86.08 · Sale (S): 1,999 @ $87.25 · Sale (S): 683 @ $87.70 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-12-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 1,190 @ $87.26 · Sale (S): 3,373 @ $88.70 · Sale (S): 3,157 @ $89.31 · Sale (S): 280 @ $90.24 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-11-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 6,111 @ $85.59 · Sale (S): 1,757 @ $86.49 · Sale (S): 132 @ $87.05 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-11-08 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 87,481 (derivative) @ $0 · Grant/award (A): 35,661 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 19,108 @ $20.93 · Option exercise (M): 19,108 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Option exercise (M): 8,000 @ $5.35 · Option exercise (M): 12,000 @ $5.35 · Option exercise (M): 14,000 @ $5.35 · Sale (S): 36,114 @ $115.26 · Sale (S): 5,886 @ $116.19 · +4 more | EDGAR |
| 2024-09-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 5,485 @ $115.60 · Sale (S): 1,686 @ $116.29 · Sale (S): 829 @ $117.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Vaxcyte, Inc. (PCVX) | Tax withholding (F): 6,337 @ $110.15 | EDGAR |
| 2024-08-20 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 4,994 @ $78.25 · Sale (S): 3,006 @ $79.14 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-07-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 3,095 @ $80.11 · Sale (S): 2,500 @ $81.06 · Sale (S): 1,479 @ $82.32 · Sale (S): 926 @ $83.14 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 7,652 @ $71.89 · Sale (S): 348 @ $72.56 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 3,544 @ $74.40 · Sale (S): 4,456 @ $75.46 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 7,624 @ $61.24 · Sale (S): 376 @ $61.90 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-03-20 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 7,764 @ $69.00 · Sale (S): 236 @ $69.64 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-03-04 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 20,000 @ $0 · Tax withholding (F): 3,795 @ $71.55 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 4,909 @ $74.08 · Sale (S): 2,751 @ $75.17 · Sale (S): 340 @ $75.80 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | Caribou Biosciences, Inc. (CRBU) | Grant/award (A): 39,500 (derivative) @ $0 | EDGAR |
| 2024-01-19 | 4 | Vaxcyte, Inc. (PCVX) | Option exercise (M): 8,000 @ $5.35 · Sale (S): 4,387 @ $60.27 · Sale (S): 3,127 @ $61.19 · Sale (S): 463 @ $61.88 · Sale (S): 23 @ $63.35 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1230724 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →